Christine A. Poon’s Form 4 filings reveal a pattern dominated by compensation-driven activity and a single concentrated sales event, with no open-market purchases across her 41 reported transactions. Her total sell value reached approximately $4.43 million, all of it occurring on October 29, 2025, in Regeneron Pharmaceuticals (REGN). That day, she executed six open-market sales totaling roughly $4.25 million, with individual transactions ranging from $65,510 to $1.79 million. These sales were paired with option exercises—$3.38 million exercised on October 29 and another $1.41 million on October 30—suggesting the disposals were tied to the maturation or exercise of equity awards rather than a gradual portfolio shift.
Outside of that concentrated REGN liquidation, Poon’s activity across Prudential Financial (PRU), Neurocrine Biosciences (NBIX), and REGN has been almost entirely mechanical. The bulk of her recent filings are “A” codes—grants or awards with no cash outlay—including recurring quarterly PRU awards in March, June, September, and December 2025, plus additional grants in May and June 2026. A May 2026 PRU transaction shows a “D” code (sale back to the issuer) valued at $181,053.70, paired with a zero-value option exercise, a common structure for settling equity obligations. Her only other notable move was a May 2026 NBIX exercise with no reported value.
The data paints a clear picture: Poon is not an active buyer or seller in the open market. Her selling is episodic and tied to option exercises, while her acquisitions are overwhelmingly compensation grants. The recent six-month window shows zero open-market purchases and zero sales, with only awards and exercises—indicating a passive, long-term holding posture rather than any directional bet on the underlying equities.
AI-assisted summary